6-K
Mereo BioPharma Group plc (MREO)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OFFOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 or15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of October, 2020
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrant’s name into English)
4^th^ Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Exhibit Index
| Exhibits | |
|---|---|
| 99.1 | Regulatory News Service Announcement dated October 12, 2020. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: October 13, 2020
| MEREO BIOPHARMA GROUP PLC | |
|---|---|
| By: | /s/ Charles Sermon |
| Name: Charles Sermon | |
| Title: General Counsel |
EX-99.1
Exhibit 99.1
Mereo BioPharma Group plc
PDMR Notification
London and RedwoodCity, Calif., October 12, 2020 – Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on October 09, 2020, Charles Sermon, General Counsel at Mereo, purchased 18,405 American Depositary Shares (ADSs) at a price of USD 2.41 per ADS.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
| 1 | Details of the person discharging managerial responsibilities | ||
|---|---|---|---|
| a) | Name | Charles Sermon | |
| 2 | Reason for the notification | ||
| a) | Position/status | General Counsel | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Mereo BioPharma Group plc | |
| b) | LEI | 213800U8JQHIJOS5AS09 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction;<br>(iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF 0.003 EACH | |
| b) | Nature of the transaction | PURCHASE | |
| c) | Price(s) and volume(s) | ||
| Volume(s) | |||
| 18,405 | |||
| d) | Aggregated information: volume, Price | ||
| e) | Date of the transaction | 2020-10-09 | |
| f) | Place of the transaction | XNMS (Nasdaq Global Market) |
All values are in British Pounds.